| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | ONCOC4 INC | 9640 MEDICAL CENTER DR | ROCKVILLE | MD | 20850-3368 | MONTGOMERY | USA | R44CA250824 | First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy | 000 | 3 | NIH | 12/21/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,000,000 ) |
| | 2022 | 2022 | ONCOC4, INC. | 9640 MEDICAL CENTER DR | ROCKVILLE | MD | 20850-3368 | MONTGOMERY | USA | R44CA250824 | First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy | 000 | 3 | NIH | 4/4/2022 | $1,000,000 |
|
| Issue Date FY: 2021 ( Subtotal = $1,000,000 ) |
| | 2021 | 2021 | ONCOC4, INC. | 9640 MEDICAL CENTER DR | ROCKVILLE | MD | 20850-3368 | MONTGOMERY | USA | R44CA250824 | First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy | 002 | 2 | NIH | 8/27/2021 | $0 |
| | 2021 | 2021 | ONCOC4, INC. | 9640 MEDICAL CENTER DR | ROCKVILLE | MD | 20850-3368 | MONTGOMERY | USA | R44CA250824 | First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy | 001 | 2 | NIH | 4/1/2021 | $1,000,000 |
|
|
